Literature DB >> 1992101

Marked elevations of serum alkaline phosphatase in patients with AIDS.

T H Payne1, D L Cohn, A J Davidson, T D Henry, J W Schaefer, P A Gabow.   

Abstract

We have observed many patients with AIDS who have unexplained marked elevations in serum alkaline phosphatase. To determine the frequency of alkaline phosphatase elevations in patients with AIDS, and to identify diagnoses, medications, and demographic factors associated with such elevations, we conducted a retrospective study of the first 90 consecutive AIDS cases in hospitals affiliated with the University of Colorado Health Sciences Center in Denver, Colorado. We found elevations of alkaline phosphatase in excess of 1,000 IU/L in 17% of consecutive patients with AIDS. This level of elevation was less frequent in patients with Kaposi's sarcoma but there was otherwise no significant association with diagnoses or medications, or transmission categories for AIDS. The majority of the patients with elevations to this level did not have documented opportunistic infections or biliary tract dilatation previously described in the "cholangitis" syndrome in AIDS patients. Other explanations for these elevations for this common laboratory finding may exist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992101

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  3 in total

1.  Natural history of AIDS related sclerosing cholangitis: a study of 20 cases.

Authors:  A Forbes; C Blanshard; B Gazzard
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

2.  Pathogenic mechanisms of caprine arthritis-encephalitis virus.

Authors:  E G Mdurvwa; P O Ogunbiyi; H S Gakou; P G Reddy
Journal:  Vet Res Commun       Date:  1994       Impact factor: 2.459

3.  Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-DOX Study Group.

Authors:  F D Goebel; D Goldstein; M Goos; H Jablonowski; J S Stewart
Journal:  Br J Cancer       Date:  1996-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.